Alopecia universalis: A rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin [1]

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 579-580

  Demirturk, Nese ^a   Aykin, Nevil ^b   Demirdal, Tuna ^a   Cevik, Figen ^b  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b Yunus Emre Devlet Hastanesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ALOPECIA; CASE REPORT; CLINICAL FEATURE; FOLLOW UP; HEPATITIS C; HUMAN; LABORATORY TEST; LETTER; MALE; THYROID FUNCTION TEST;

ALOPECIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33845263288     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Zeuzem S. Treatment of hepatitis C virus infection. Schweiz Rundsch Med Prax 2005; 94: 721-6.
2. Taliani G, Biliotti E, Capanni M, Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitits C. Chemother 2005; 17: 212-4.
3. Alexis A, Dudda-Subramanya R, Sinha A. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004; 14: 364-70.
4. Trapero M, Garcia-Buey L, Munoz C, Viton M, Moreno-Monteagudo JA, Borque W, Quintana NE, Moreno-Otero R. Maintenance of T1 response as induced during PEG-IFN plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev Esp Enferm Dig 2005; 97: 481-90.
5. Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006: 16: 94-5.